Compare PSN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSN | MIRM |
|---|---|---|
| Founded | 1944 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.7B |
| IPO Year | 2019 | 2019 |
| Metric | PSN | MIRM |
|---|---|---|
| Price | $56.52 | $99.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $79.18 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.1M | 599.7K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.77 | ★ 74.59 |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $6,364,245,000.00 | $19,138,000.00 |
| Revenue This Year | $5.87 | $26.22 |
| Revenue Next Year | $7.61 | $22.04 |
| P/E Ratio | $115.71 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.23 | $47.89 |
| 52 Week High | $89.50 | $114.99 |
| Indicator | PSN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 53.73 |
| Support Level | $48.81 | $95.68 |
| Resistance Level | $59.00 | $107.51 |
| Average True Range (ATR) | 2.50 | 4.25 |
| MACD | -0.20 | 0.20 |
| Stochastic Oscillator | 40.69 | 77.87 |
Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.